Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b

Expert Opinion on Biological Therapy

Volumn 9, Issue 4, 2009, Pages 387-397

  Durelli, L ^a,b   Barbero, P ^b   Cucci, A ^b   Ferrero, B ^b   Ricci, A ^b   Contessa, G ^b   De Mercanti, S ^b   Ripellino, P ^b   Lapuma, D ^b   Viglietta, E ^b   Bergui, M ^c   Versino, E ^c   Clerico, M ^b  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^b Facoltà di Medicina e Chirurgia S Luigi Gonzaga   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

375 g IFN 1b dose; IFN ; Multiple sclerosis; Neutralizing antibodies; OPTIMS study; Treatment response

Indexed keywords

INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE;

EID: 67649262238     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902762781     Document Type: Article

References (66)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentre, randomized, double- blind, placebo-controlled trial. Neurology 1993;43:655-661
2. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicentre, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-667
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol 1996;39:285-294 (Pubitemid 26100751)
4. PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
5. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460 (Pubitemid 34457761)
6. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology 2002;59:1496-1506 (Pubitemid 35387053)
7. Pachner AR. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology 1997;49:647-650 (Pubitemid 27427998)
8. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-1272 (Pubitemid 28240338)
9. Cook SD, Quinless JR, Jotkowitz A, Beaton P. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 2001;57:1080-1084 (Pubitemid 32880206)
10. Vallittu AM, Halminen M, Peltoniemi J, et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 2002;58:1786-1790 (Pubitemid 34663579)
11. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003;60:634-639 (Pubitemid 36246082)
12. Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243 (Pubitemid 29177928)
13. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2007;68:977-984
14. Hartung HP, Polman C, Bertolotto A, et al. Neutralising antibodies to interferon beta in multiple sclerosis. Expert panel report. J Neurol 2007;254(7):827-837 (Pubitemid 47222316)
15. IFNB multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894
16. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191 •• Long-term observational study in a large patient sample. (Pubitemid 37255344)
17. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. Neurology 2004;62:2031-2037 (Pubitemid 38738217)
18. Francis GS, Rice GP, Alsop JC, et al. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55 (Pubitemid 40967775)
19. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005;65:40-47 •• Long-term observational study nested in an RCT. (Pubitemid 40967774)
20. Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and a delayed impact on efficacy of interferon-beta. Mult Scler 2008;14:212-218 (Pubitemid 351639630)
21. Boz C, Oger J, Gibbs E, Grossberg SE. Neurologists of the UBC MS Clinic. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 2007;13:1127-1137
22. Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003;60:37-43 (Pubitemid 36070641)
23. Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-138 •• The correct statistical approach to longitudinal studies. (Pubitemid 38499903)
24. Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-1279 (Pubitemid 29177937)
25. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39 (Pubitemid 40967773)
26. Hesse D, Sorensen PS. Using measurements of neutralizing antibodies: the challenge of IFN-β therapy. Eur J Neurol 2007;14:850-859
27. Bertolotto A, Malucchi S, Milano E, et al. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000;48:95-100 (Pubitemid 30608666)
28. Pozzilli C, Antonini G, Bagnato F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis. J Neurol 2002;249:50-56 (Pubitemid 34119023)
29. Patti F, Cataldi ML, Nicoletti F, et al. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71:404-407 (Pubitemid 32772544)
30. Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002;58:314-317 (Pubitemid 34084230)
31. Durelli L, Barbero P, Bergui M, et al. The OPTimization of interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders. J Neurol 2008;255:1315-1323
32. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231 (Pubitemid 13158528)
33. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452 (Pubitemid 14237132)
34. Files JG, Gray JL, Do LT, et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998;18:1019-1024 (Pubitemid 29011608)
35. Pungor E Jr, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998;18:1025-1030 (Pubitemid 29011609)
36. Whitley E, Ball J. Statistic review 4: sample size calculation. Crit Care 2002;6:335-341 (Pubitemid 34863702)
37. Altman DG. How large a sample? In: Gore SM, Altman DG, editors, Statistics in Practice. London: British Medical Association, 1982
38. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med 1992;11:1825-1839 (Pubitemid 23015633)
39. Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health 1993;14:43-68 (Pubitemid 23161711)
40. Rothman KJ, Greenland S. Modern Epidemiology. Second edition. Philadelphia: Lippincott-Ravens Publishers, 1998
41. Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 1998;19:209-211 (Pubitemid 28275571)
42. Rousset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-1893
43. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994;93:424-428 (Pubitemid 24030864)
44. Milella M, Antonelli G, Santantonio T, et al. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Hepatogastroenterology 1995;42:201-204
45. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52 (Pubitemid 32634271)
46. Khan O, Zabad R, Caon C, et al. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2002;16:563-578 (Pubitemid 34827912)
47. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology 2002;59(Suppl 3):S1-S33
48. Rio J, Nos C, Tintore M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002;52:400-406
49. Chiu AW, Ehrmantraut M, Richert ND, et al. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging. Clin Exp Immunol 2007;150:61-67 (Pubitemid 47383299)
50. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16 (Pubitemid 26052212)
51. Calabresi PA, Stone LA, Bash CN, et al. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997;48:1446-1448 (Pubitemid 27240580)
52. McFarland HF, Frank JA, Albert PS. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766
53. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFN beta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006;67:1681-1683 (Pubitemid 44747946)
54. Traboulsee A, Al-Sabbagh A, Bennett R, et al. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study. BMC Neurol 2008;8:11 (Pubitemid 351659538)
55. The PRISMS (Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis) Study Group; and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-b-1a in relapsing MS. Neurology 2001;56:1628-1636
56. Sandberg-Wollheim M, Stam MM, Alsop J, Abdalla J. The PRISMS (Preventing of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) study report on neutralizing antibodies up to year 6 of treatment [abstract]. Neurology 2003;60(Suppl 1):A482-3
57. Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K. Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Mult Scler 2008;14:837-842
58. Farrel A, Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler 2007;13:567-577 (Pubitemid 46939521)
59. Lok AS, Lai CL, Leung EK. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990;12:1266-1270
60. Deisenhammer F, Millonig A, Gneiss C, et al. High dose intravenous interferon-beta in MS patients with neutralizing antibodies (HINABS). A pilot study [abstract]. Neurology 2008;70:A272-3
61. Oger J, Francis G, Chang P. Chang on behalf of the PRISMS Study Group. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: The PRISMS study. J Neurol Sci 2005;237:45-52
62. Brackmann HH, Lenk H, Scharrer I, et al. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999;5:203-206 (Pubitemid 29326771)
63. Hay CR, Baglin TP, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK haemophilia centre doctors' organization (UKHCDO). Br J Haematol 2000;111:78-90 (Pubitemid 30832435)
64. Kakavanos R, Turner CT, Hopwood JJ, et al. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003;361:1608-1613 (Pubitemid 36578998)
65. Ahn J, Feng X, Patel N, et al. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front Biosci 2004;9:1547-1555 (Pubitemid 38918613)
66. O'Connor P, Arnason B, Comi G, et al. Interferon beta-1b 500 mcg, Interferon beta-1b 250 mcg and Glatiramer Acetate: Primary Outcomes of the Betaferon®/Betaseron® efficacy yielding outcomes of a new dose study [abstract]. Neurology 2008;71:153